Atsushi Kawakami Selected Research

Antirheumatic Agents (DMARD)

5/2024	Influences of advanced age in rheumatoid arthritis: A multicentre ultrasonography cohort study.
11/2023	Denosumab improves bone mineral density and microarchitecture in rheumatoid arthritis: randomized controlled trial by HR-pQCT.
3/2023	Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
12/2022	Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
1/2022	Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
1/2021	Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study.
8/2020	Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
7/2020	Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
1/2020	Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.
1/2019	Ultrasound-Proven Severe Synovitis Induced by PD-1 Inhibitor Therapy in a Patient Predisposed to Seronegative Inflammatory Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsushi Kawakami Research Topics

Disease

105	Rheumatoid Arthritis 05/2024 - 02/2004
30	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2024 - 01/2004
22	Fever (Fevers) 02/2024 - 09/2011
20	Inflammation (Inflammations) 03/2024 - 02/2004
20	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 12/2003
20	Familial Mediterranean Fever (Periodic Disease) 12/2022 - 05/2013
18	Arthritis (Polyarthritis) 12/2023 - 02/2007
18	Synovitis 01/2023 - 02/2004
17	Infections 02/2024 - 04/2002
16	Interstitial Lung Diseases (Interstitial Lung Disease) 05/2023 - 08/2006
16	Dermatomyositis (Dermatopolymyositis) 11/2022 - 08/2006
15	Immunoglobulin G4-Related Disease 02/2024 - 10/2011
14	Edema (Dropsy) 02/2024 - 02/2007
12	Neoplasms (Cancer) 04/2024 - 03/2003
12	Adult-Onset Still's Disease 12/2023 - 01/2014
12	Takayasu Arteritis (Arteritis, Takayasu's) 04/2022 - 01/2006
10	Rheumatic Diseases (Rheumatism) 09/2023 - 10/2011
10	Vasculitis (Vasculitides) 01/2023 - 01/2006
8	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 02/2024 - 07/2008
8	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2024 - 01/2012
8	Systemic Scleroderma (Systemic Sclerosis) 01/2023 - 02/2014
8	Melanoma (Melanoma, Malignant) 03/2021 - 01/2015
7	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2023 - 12/2007
7	Type 2 Diabetes Mellitus (MODY) 12/2022 - 06/2016
7	Myositis (Idiopathic Inflammatory Myopathies) 07/2021 - 01/2015
6	Diabetes Mellitus 02/2024 - 01/2014
6	Pain (Aches) 02/2024 - 04/2015
6	Herpes Zoster 10/2023 - 01/2016
6	Lupus Nephritis 01/2021 - 01/2014
5	Fibrosis (Cirrhosis) 02/2024 - 11/2013
5	Lymphadenopathy 02/2024 - 01/2016
5	Castleman Disease (Castleman's Disease) 02/2024 - 07/2020
5	Thrombocytopenia (Thrombopenia) 11/2023 - 12/2011
5	Glomerulonephritis 01/2023 - 06/2009
5	Glucose Intolerance 08/2021 - 01/2010
5	Muscle Weakness 08/2020 - 10/2010
5	Connective Tissue Diseases (Connective Tissue Disease) 01/2019 - 03/2013
5	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 01/2017 - 04/2002
4	Macrophage Activation Syndrome 12/2023 - 04/2013

Drug/Important Bio-Agent (IBA)

30	AntibodiesIBA 02/2024 - 09/2003
30	tocilizumab (atlizumab)FDA Link 02/2024 - 02/2010
30	CytokinesIBA 01/2024 - 03/2002
27	AutoantibodiesIBA 02/2024 - 12/2003
27	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2011
21	Prednisolone (Predate)FDA LinkGeneric 04/2022 - 01/2004
19	Antirheumatic Agents (DMARD)IBA 05/2024 - 04/2012
19	SteroidsIBA 01/2024 - 01/2006
17	Colchicine FDA LinkGeneric 12/2022 - 01/2014
16	GlucocorticoidsIBA 03/2024 - 01/2006
16	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2024 - 01/2002
16	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2023 - 07/2007
15	Immunoglobulin G (IgG)IBA 02/2024 - 10/2011
15	C-Reactive ProteinIBA 08/2023 - 11/2007
15	Methotrexate (Mexate)FDA LinkGeneric 03/2023 - 01/2006
15	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2022 - 08/2006
14	Interleukin-6 (Interleukin 6)IBA 09/2023 - 11/2007
14	EnzymesIBA 08/2023 - 12/2003
13	Tumor Necrosis Factor InhibitorsIBA 10/2023 - 02/2010
13	Anti-Citrullinated Protein AntibodiesIBA 01/2022 - 01/2006
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2024 - 12/2007
11	Antigen-Antibody Complex (Immune Complex)IBA 01/2023 - 06/2011
10	Tacrolimus (Prograf)FDA LinkGeneric 02/2024 - 07/2007
10	Janus Kinase InhibitorsIBA 10/2023 - 12/2016
10	Insulin (Novolin)FDA Link 02/2023 - 01/2012
10	Infliximab (Remicade)FDA Link 08/2020 - 01/2006
9	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2015
9	Glucose (Dextrose)FDA LinkGeneric 02/2023 - 03/2015
9	Abatacept (Orencia)FDA Link 01/2023 - 05/2013
9	InflammasomesIBA 12/2022 - 11/2015
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 01/2009
8	Adalimumab (Humira)FDA Link 02/2024 - 09/2011
8	ImmunosorbentsIBA 01/2023 - 12/2003
8	Rheumatoid FactorIBA 12/2019 - 01/2006
7	Cyclosporine (Ciclosporin)FDA LinkGeneric 02/2024 - 08/2006
7	Peroxidase (Myeloperoxidase)IBA 02/2024 - 07/2007
7	AcidsIBA 12/2023 - 03/2011
7	Immunoglobulin M (IgM)IBA 10/2023 - 01/2006
7	AntigensIBA 01/2023 - 01/2006
7	Methylprednisolone FDA LinkGeneric 10/2019 - 01/2006
6	Etanercept (Enbrel)FDA Link 02/2024 - 01/2009
6	ChemokinesIBA 01/2024 - 01/2017
6	Interleukin-17 (Interleukin 17)IBA 10/2021 - 01/2016
6	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 03/2020 - 02/2015
5	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 02/2024 - 11/2019
5	Denosumab FDA Link 01/2024 - 05/2019
5	tofacitinibIBA 10/2023 - 12/2016
5	Complement System Proteins (Complement)IBA 01/2022 - 11/2015
5	Interleukin-18 (Interleukin 18)IBA 01/2022 - 02/2004
5	cyclic citrullinated peptideIBA 03/2021 - 01/2006
5	peficitinibIBA 03/2021 - 10/2019
5	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 10/2010
5	InterleukinsIBA 01/2021 - 01/2014
5	Uric Acid (Urate)IBA 01/2021 - 06/2008
5	Anti-Bacterial Agents (Antibiotics)IBA 03/2020 - 12/2011
5	Ferritins (Ferritin)IBA 01/2020 - 01/2015
5	DNA (Deoxyribonucleic Acid)IBA 10/2018 - 01/2006
4	Rituximab (Mabthera)FDA Link 02/2024 - 06/2018
4	Glucagon (Glukagon)FDA Link 01/2024 - 01/2020
4	HLA-DRB1 Chains (HLA DRB1)IBA 01/2024 - 06/2011

Therapy/Procedure

66	Therapeutics 02/2024 - 01/2006